Comparison of effect of Tacrolimus and cyclosporine in patients with autoimmune nephropathy

Comparison of effect of Tacrolimus and cyclosporine in patients with Idiopathic membranous nephropathy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014101912685N3

Enrollment

Registered

2014-11-26

Start date

2014-10-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic membranous nephropathy. Chronic nephritic syndrome

Interventions

Intervention 1: Intervention group: Tacrolimus for 6 month with dose of 0.5 mg/kg/day. Intervention 2: Control group: Cyclosporine for 6 month with dose of 6 mg/kg/day.

Treatment - Drugs

Intervention group: Tacrolimus for 6 month with dose of 0.5 mg/kg/day

Control group: Cyclosporine for 6 month with dose of 6 mg/kg/day

Eligibility

Sex/Gender

All

Age

15 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Idiopathic membranous nephropathy had been confirmed by kidney biopsy; Patients have proteinuria more than 3000 mg per day. Exclusion criteria: Patients with secondary Idiopathic membranous nephropathy; Patients with sensitivity to Tacrolimus.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Urine protein. Timepoint: Before intervention, after 3 month of intervention and after 6 month of intervention. Method of measurement: Urine biochemistry test.;Kidney biopsy. Timepoint: Before intervention. Method of measurement: Kidney biopsy test.;Blood urea. Timepoint: Before intervention, after 3 month of intervention and after 6 month of intervention. Method of measurement: Blood biochemistry test.;Blood creatinin. Timepoint: Before intervention, after 3 month of intervention and after 6 month of intervention. Method of measurement: Blood biochemistry test.	—

Measure

Time frame

Urine protein. Timepoint: Before intervention, after 3 month of intervention and after 6 month of intervention. Method of measurement: Urine biochemistry test.;Kidney biopsy. Timepoint: Before intervention. Method of measurement: Kidney biopsy test.;Blood urea. Timepoint: Before intervention, after 3 month of intervention and after 6 month of intervention. Method of measurement: Blood biochemistry test.;Blood creatinin. Timepoint: Before intervention, after 3 month of intervention and after 6 month of intervention. Method of measurement: Blood biochemistry test.

—

Secondary

Measure	Time frame
Fasting blood sugar. Timepoint: Before intervention, after 3 month of intervention and after 6 month of intervention. Method of measurement: Blood biochemistry test.;Blood triglyceride. Timepoint: Before intervention, after 3 month of intervention and after 6 month of intervention. Method of measurement: Blood biochemistry test.;Blood cholesterol. Timepoint: Before intervention, after 3 month of intervention and after 6 month of intervention. Method of measurement: Blood biochemistry test.	—

Measure

Time frame

Fasting blood sugar. Timepoint: Before intervention, after 3 month of intervention and after 6 month of intervention. Method of measurement: Blood biochemistry test.;Blood triglyceride. Timepoint: Before intervention, after 3 month of intervention and after 6 month of intervention. Method of measurement: Blood biochemistry test.;Blood cholesterol. Timepoint: Before intervention, after 3 month of intervention and after 6 month of intervention. Method of measurement: Blood biochemistry test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamid Reza Omrani

Kermanshah University of Medical Sciences

hamidomrani@kums.ac.ir+98 83 3837 0557

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026